Logo image of GUD.CA

KNIGHT THERAPEUTICS INC (GUD.CA) Stock Fundamental Analysis

TSX:GUD - CA4990531069 - Common Stock

6.5 CAD
+0.1 (+1.56%)
Last: 8/29/2025, 7:00:00 PM
Fundamental Rating

4

Overall GUD gets a fundamental rating of 4 out of 10. We evaluated GUD against 35 industry peers in the Pharmaceuticals industry. While GUD seems to be doing ok healthwise, there are quite some concerns on its profitability. GUD shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year GUD has reported negative net income.
In the past year GUD had a positive cash flow from operations.
In multiple years GUD reported negative net income over the last 5 years.
GUD had a positive operating cash flow in 4 of the past 5 years.
GUD.CA Yearly Net Income VS EBIT VS OCF VS FCFGUD.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M

1.2 Ratios

GUD's Return On Assets of 0.04% is fine compared to the rest of the industry. GUD outperforms 65.71% of its industry peers.
GUD has a better Return On Equity (0.05%) than 68.57% of its industry peers.
Industry RankSector Rank
ROA 0.04%
ROE 0.05%
ROIC N/A
ROA(3y)-1.39%
ROA(5y)0.29%
ROE(3y)-1.78%
ROE(5y)0.26%
ROIC(3y)N/A
ROIC(5y)N/A
GUD.CA Yearly ROA, ROE, ROICGUD.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2 -2 4

1.3 Margins

GUD has a better Profit Margin (0.10%) than 65.71% of its industry peers.
In the last couple of years the Profit Margin of GUD has declined.
The Gross Margin of GUD (42.92%) is better than 65.71% of its industry peers.
GUD's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM N/A
PM (TTM) 0.1%
GM 42.92%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-43.41%
PM growth 5Y-47.95%
GM growth 3Y-0.3%
GM growth 5Y-3.67%
GUD.CA Yearly Profit, Operating, Gross MarginsGUD.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K 2K 3K

More info and screens

5

2. Health

2.1 Basic Checks

GUD does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for GUD has been reduced compared to 1 year ago.
Compared to 5 years ago, GUD has less shares outstanding
GUD has a better debt/assets ratio than last year.
GUD.CA Yearly Shares OutstandingGUD.CA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M
GUD.CA Yearly Total Debt VS Total AssetsGUD.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

An Altman-Z score of 2.21 indicates that GUD is not a great score, but indicates only limited risk for bankruptcy at the moment.
GUD has a Altman-Z score of 2.21. This is amongst the best in the industry. GUD outperforms 85.71% of its industry peers.
GUD has a Debt/Equity ratio of 0.11. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of GUD (0.11) is better than 65.71% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.11
Debt/FCF N/A
Altman-Z 2.21
ROIC/WACCN/A
WACC9.7%
GUD.CA Yearly LT Debt VS Equity VS FCFGUD.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M 800M 1B

2.3 Liquidity

A Current Ratio of 2.47 indicates that GUD has no problem at all paying its short term obligations.
GUD's Current ratio of 2.47 is fine compared to the rest of the industry. GUD outperforms 62.86% of its industry peers.
A Quick Ratio of 1.50 indicates that GUD should not have too much problems paying its short term obligations.
The Quick ratio of GUD (1.50) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 2.47
Quick Ratio 1.5
GUD.CA Yearly Current Assets VS Current LiabilitesGUD.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

7

3. Growth

3.1 Past

GUD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 100.00%, which is quite impressive.
Measured over the past years, GUD shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -13.46% on average per year.
The Revenue has grown by 13.82% in the past year. This is quite good.
The Revenue has been growing by 50.87% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)100%
EPS 3Y-25.31%
EPS 5Y-13.46%
EPS Q2Q%-550%
Revenue 1Y (TTM)13.82%
Revenue growth 3Y15.1%
Revenue growth 5Y50.87%
Sales Q2Q%12.33%

3.2 Future

GUD is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 53.46% yearly.
GUD is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 9.68% yearly.
EPS Next Y-330.28%
EPS Next 2Y10.09%
EPS Next 3Y50.87%
EPS Next 5Y53.46%
Revenue Next Year14.81%
Revenue Next 2Y12.31%
Revenue Next 3Y8.59%
Revenue Next 5Y9.68%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
GUD.CA Yearly Revenue VS EstimatesGUD.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M
GUD.CA Yearly EPS VS EstimatesGUD.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.2 -0.2 0.4

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

GUD is valuated quite expensively with a Price/Forward Earnings ratio of 107.26.
68.57% of the companies in the same industry are more expensive than GUD, based on the Price/Forward Earnings ratio.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.76, GUD is valued quite expensively.
Industry RankSector Rank
PE N/A
Fwd PE 107.26
GUD.CA Price Earnings VS Forward Price EarningsGUD.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, GUD is valued a bit cheaper than 65.71% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 14.36
GUD.CA Per share dataGUD.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

GUD's earnings are expected to grow with 50.87% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y10.09%
EPS Next 3Y50.87%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for GUD!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

KNIGHT THERAPEUTICS INC

TSX:GUD (8/29/2025, 7:00:00 PM)

6.5

+0.1 (+1.56%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-07 2025-08-07/bmo
Earnings (Next)11-05 2025-11-05
Inst Owners10.02%
Inst Owner ChangeN/A
Ins Owners1.85%
Ins Owner ChangeN/A
Market Cap647.73M
Analysts78
Price Target7.96 (22.46%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-224.57%
Min EPS beat(2)-815.07%
Max EPS beat(2)365.93%
EPS beat(4)2
Avg EPS beat(4)-21.94%
Min EPS beat(4)-815.07%
Max EPS beat(4)461.4%
EPS beat(8)3
Avg EPS beat(8)-230%
EPS beat(12)6
Avg EPS beat(12)-123.05%
EPS beat(16)7
Avg EPS beat(16)-384.28%
Revenue beat(2)2
Avg Revenue beat(2)5.97%
Min Revenue beat(2)0.88%
Max Revenue beat(2)11.06%
Revenue beat(4)4
Avg Revenue beat(4)5.89%
Min Revenue beat(4)0.88%
Max Revenue beat(4)11.06%
Revenue beat(8)7
Avg Revenue beat(8)5%
Revenue beat(12)11
Avg Revenue beat(12)8.91%
Revenue beat(16)14
Avg Revenue beat(16)9.42%
PT rev (1m)3.12%
PT rev (3m)3.21%
EPS NQ rev (1m)-110.42%
EPS NQ rev (3m)-105.68%
EPS NY rev (1m)-302.85%
EPS NY rev (3m)-302.85%
Revenue NQ rev (1m)-0.5%
Revenue NQ rev (3m)18.08%
Revenue NY rev (1m)3.65%
Revenue NY rev (3m)4.47%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 107.26
P/S 1.68
P/FCF N/A
P/OCF 21.3
P/B 0.85
P/tB 2.25
EV/EBITDA 14.36
EPS(TTM)0
EYN/A
EPS(NY)0.06
Fwd EY0.93%
FCF(TTM)-0.01
FCFYN/A
OCF(TTM)0.31
OCFY4.69%
SpS3.86
BVpS7.66
TBVpS2.89
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 0.04%
ROE 0.05%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 0.1%
GM 42.92%
FCFM N/A
ROA(3y)-1.39%
ROA(5y)0.29%
ROE(3y)-1.78%
ROE(5y)0.26%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-43.41%
PM growth 5Y-47.95%
GM growth 3Y-0.3%
GM growth 5Y-3.67%
F-Score6
Asset Turnover0.37
Health
Industry RankSector Rank
Debt/Equity 0.11
Debt/FCF N/A
Debt/EBITDA 1.96
Cap/Depr 62.43%
Cap/Sales 8.29%
Interest Coverage N/A
Cash Conversion 72.19%
Profit Quality N/A
Current Ratio 2.47
Quick Ratio 1.5
Altman-Z 2.21
F-Score6
WACC9.7%
ROIC/WACCN/A
Cap/Depr(3y)40.08%
Cap/Depr(5y)130.51%
Cap/Sales(3y)6.77%
Cap/Sales(5y)24.55%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)100%
EPS 3Y-25.31%
EPS 5Y-13.46%
EPS Q2Q%-550%
EPS Next Y-330.28%
EPS Next 2Y10.09%
EPS Next 3Y50.87%
EPS Next 5Y53.46%
Revenue 1Y (TTM)13.82%
Revenue growth 3Y15.1%
Revenue growth 5Y50.87%
Sales Q2Q%12.33%
Revenue Next Year14.81%
Revenue Next 2Y12.31%
Revenue Next 3Y8.59%
Revenue Next 5Y9.68%
EBIT growth 1Y-652.93%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year371.57%
EBIT Next 3Y73.66%
EBIT Next 5Y53.47%
FCF growth 1Y-140.33%
FCF growth 3YN/A
FCF growth 5Y23.85%
OCF growth 1Y60.79%
OCF growth 3Y-6.66%
OCF growth 5Y51.14%